Search
Displaying 321–330 of 737 for “retinitis clinical trial”
-
Eye on the Cure Podcast | Episode 77: Dr. Bob Bell
Eye on the CureDr. Bell, the CSO of Ascidian Therapeutics, talks about STELLAR, the company’s Phase ½ clinical trial for its emerging RNA-rewriting therapy for Stargardt disease (ABCA4 mutations).
-
My Retina Tracker Genetic Testing Program
The Foundation Fighting Blindness, in partnership with PreventionGenetics and InformedDNA®, offers an open access, no-cost genetic testing program called the My Retina Tracker® Genetic Testing Program.
-
ARVO 2016: Emerging Drug Targets Toxic Build-Up in Stargardt Disease
Research NewsIn August 2015, the biotech company Alkeus launched a multi-center TEASE Phase II clinical trial for the drug ALK-001.
-
Celebrating National DNA Day with Dr. Benjamin Bakall
Beacon StoriesApril 25 is National DNA Day, commemorating the completion of the Human Genome Project and the discovery of DNA’s double helix. To celebrate, we’re spotlighting Dr. Benjamin Bakall, a retinal specialist and ophthalmologist at Associated Retina Consultants in Phoenix, Arizona. Dr. Bakall’s dedication to genetics and patient care highlights the importance of genetic testing in advancing treatments and cures for inherited retinal diseases.
-
Research News
Clinical trial participants with advanced vision loss from RP were able to identify fruits and vegetables
-
Why Genetic Testing is Important
An Overview of Genetic Testing for Inherited Retinal Degenerative Diseases
-
Advocacy Foundation News
Chairwoman Capito, Ranking Member Baldwin, and members of the Senate Appropriations Labor, Health and Human Services, Education, and Related Agencies Subcommittee, the Foundation Fighting Blindness appreciates the opportunity to provide written testimony to the subcommittee as an outside witness.
-
Disease
Mutations in CRB1 are a relatively common cause of several inherited retinal degenerations, including: Leber congenital amaurosis (LCA) retinitis pigmentosa (RP), and macular dystrophy (MD).
-
Eye on the Cure Podcast | Episode 59: Dr. Robert MacLaren
Eye on the CureDr. Robert MacLaren, a world-renowned retinal surgeon, clinical trial investigator, and research lab leader at the University of Oxford, talks to host Ben Shaberman about the successes and challenges in retinal gene therapy development and clinical trials, as well as advances in robotics for improving retinal surgery outcomes.
-
IZERVAY Approved by FDA for Treatment of Geographic Atrophy Secondary to Advanced Dry AMD
Research NewsIn two Phase 3 clinical trials, IZERVAY slowed the growth rate of lesions, the regions of cell loss in the central retina, associated with geographic atrophy (GA)
%20(1).png)
